October 13, 2016
Daiichi Sankyo said on October 12 that it has launched a global PIII trial, dubbed QuANTUM-First, in the US, Europe, and Asia for its cancer agent quizartinib with the aim of obtaining its approval as a first-line treatment for FLT3-ITD-positive...read more